Navigation Links
URL Pharma Acquires PharmPro Manufacturing Facility and Equipment
Date:8/3/2009

PHILADELPHIA, Aug. 3 /PRNewswire/ -- URL Pharma, a leading specialty pharmaceutical company, today announced it has acquired the assets of PharmPro, a division of Fluid Air, Inc. The facility, located in Aurora, Illinois, is FDA inspected and DEA (Drug Enforcement Agency) licensed. The acquisition expands the capacity and capabilities of URL Pharma's product development and manufacturing operations.

The 19,000 sq. ft. state-of-the-art facility includes fluid bed technology, enabling water and solvent coating processes critical to the development and manufacture of a wide array of modified release products. The acquisition also includes DuraGran(R), a proprietary platform technology that enables the efficient production of uniform, small granules in the development and manufacture of modified release dosage forms.

"This acquisition brings fluid bed technology in-house, enabling us to develop and manufacture a broad range of products for our pharmaceutical technology and brand pipelines," commented Richard H. Roberts, M.D., Ph.D., URL Pharma's President and Chief Executive Officer. "As part of this transaction, 17 former Fluid-Air employees, many with critical engineering expertise, will join URL Pharma and help integrate the new technology into our product development and manufacturing operations."

About URL Pharma

URL Pharma, Inc., headquartered in Philadelphia, Pennsylvania, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a profitable, technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. The Company's profits are derived predominantly from its exclusive products and technologies. For more information, visit www.urlpharma.com.


'/>"/>
SOURCE URL Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
2. Professor Bruce Beutler Joins aTyr Pharmas Scientific Advisory Board
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
4. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
5. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
6. US Discount Online Pharmacy Expressdelivery.biz Can Guarantee Safe and Enjoyable Shopping Experience With buySAFE Certificate
7. Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment
8. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
9. PharmaForce Inc. Receives FDA Approval for First Generic of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP
10. PDL BioPharma Announces Second Quarter 2009 Financial Results
11. Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: